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Abstract
Background: Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-derived reactive oxygen species
(ROS) not only can promote cancer progression, but also they have recently emerged as mediators of the mucosal
immune system. However, the roles and clinical relevance of the collective or individual NADPH oxidase (NOX)
family genes in cervical cancer have not been studied.
Methods: We investigated the clinical significance of the NOX family genes using data from 307 patients with
cervical cancer obtained from The Cancer Genome Atlas. Bioinformatics and experimental analyses were performed
to examine NOX family genes in cervical cancer patients.
Results: Dual Oxidase1 (DUOX1) and Dual Oxidase 2 (DUOX2) mRNA levels were upregulated 57.9- and 67.5-fold,
respectively, in cervical cancer patients. The protein expression of DUOX1, DUOX2, and NOX2 also identified in
cervical squamous cell carcinoma tissues. Especially, DUOX1 and DUOX2 mRNA levels were significantly increased in
patients infected with human papillomavirus (HPV) 16. Moreover, high DUOX1 mRNA levels were significantly
associated with both favorable overall survival and disease-free survival in cervical cancer patients. High NOX2
mRNA levels was significantly associated with favorable overall survival. Gene set enrichment analyses revealed that
high DUOX1 and NOX2 expression was significantly correlated with the enrichment of immune pathways related to
interferon (IFN)-alpha, IFN-gamma, and natural killer (NK) cell signaling. Cell-type identification by estimating relative
subsets of known RNA transcript analyses indicated that the fraction of innate immune cells, including NK cells,
monocytes, dendritic cells, and mast cells, was elevated in patients with high DUOX1 expression.
Conclusions: DUOX1 and NOX2 expression are associated with mucosal immunity activated in cervical squamous
cell carcinoma and predicts a favorable prognosis in cervical cancer patients.
Keywords: NADPH oxidases, Dual oxidases, Uterine cervical neoplasms, Papillomaviridae, Survival, Disease-free
survival
Background
Human papillomavirus (HPV) is the primary etiologic
agent of cervical cancer [1]. However, HPV alone is not
sufficient for tumor progression; the clinical manifest-
ation of HPV infection depends on the immune re-
sponse of the host [2]. Tumors are recognized by the
immune system and their development can be stopped
or controlled through a process known as immunosur-
veillance [3]. The mucosal epithelium represents the first
line of defense against virus invasion. An immature or
weakened innate immunity of the uterine cervical epi-
thelium may exacerbate viral infection. Therefore, des-
pite the improvements in vaccines against HPV, more
studies are needed to identify new therapeutic inducers
for the reinforcement of the innate immune responses
against HPV infection in cervical cancer patients.
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The NADPH oxidase (NOX) family, the major family
of enzymes that catalyze reactive oxygen species (ROS)
production, comprises seven members: NOX1–5, dual
oxidase (DUOX) 1, and DUOX2 [4]. ROS induce oxida-
tive stress and diverse inflammatory responses [5]. Ex-
cessive ROS production by NOX homologs as a result of
chronic inflammation can also promote proliferative and
invasive malignancies [6]. However, oxidative innate im-
mune defense mechanism mediated by NADPH oxidase
family members has been emerged, especially, DUOX
plays an important role in host mucosal immunity by
producing hydrogen peroxide [7–9]. Host-defense prop-
erties of DUOX have also been identified in non-
mammalian organisms [10–13]. Homologs of DUOX are
found in nearly all multicellular organisms, and DUOX
enzymes seem to be evolved to fundamentally serve host
immune defense [14]. DUOX1 and DUOX2 may have
unique roles in specific arms of the innate immune re-
sponse. Nevertheless, the immunologic effect of DUOX
in the uterine cervical mucosa, which provides the first
line of defense to HPV invasion, especially in cervical
cancer, has not yet been investigated.
The present study aimed to investigate whether NOX
family members are involved in cervical cancer progres-
sion or host immunity in response to cervical cancer.
We used data from 307 cervical cancer patients obtained
from The Cancer Genome Atlas (TCGA). Indeed, we
discovered a prognostic value of DUOX1 and NOX2 ex-
pression in cervical cancer patients, and we attempted to
elucidate the underlying mechanisms by using bioinfor-
matics analyses, including gene set enrichment analysis
(GSEA) and cell-type identification by estimating relative
subsets of known RNA transcript (CIBERSORT). More-
over, we analyzed the protein expression of NOX2,
DUOX1, and DUOX2 using clinical tissue samples from
cervical cancer patients.
Methods
Gene and protein expression profiles
RNAseqV2-RSEM_genes and clinical data from 307 Cer-
vical Squamous Cell Carcinoma and Endocervical
Adenocarcinoma (CESC) samples and 3 normal control
samples were obtained from The Cancer Genome Atlas
(http://portal.gdc.cancer.gov/) and Firebrowse (http://
firebrowse.org/) for gene expression analysis. The valid-
ation set (GSE75132) of 30 samples with persistent HPV
16 infection and 11 normal control samples was down-
loaded from the Gene Expression Omnibus (GEO) data-
base (https://www.ncbi.nlm.nih.gov/geo/). Raw data were
initially processed in R v.3.2.5 (http://www.r-project.org).
Chip data were normalized with RankNormalize in Gen-
ePattern (http://www.broadinstitute.org/cancer/software/
genepattern/). Gene Expression Profiling Interactive
Analysis (GEPIA; http://gepia.cancer-pku.cn/) was
utilized to compare mRNA expression between cervical
cancer patients based on data from TCGA database
(https://portal.gdc.cancer.gov/) and 13 normal controls
based on data from The Genotype-Tissue Expression
(GTEx) Project from the Broad Institute of MIT and
Harvard (www.gtexportal.org). Human normal tissue
distribution of DUOX1, DUOX2, and NOX2 was ana-
lyzed based on RNAseq data extracted from the GTEx
project. Protein expression and immunohistochemical
(IHC) staining data were obtained from the Human Pro-
tein Atlas (HPA) (http://www.proteinatlas.org).
Western blotting
Total protein samples were isolated from frozen liver
tissue using RIPA lysis buffer, containing protease
and phosphatase inhibitor cocktail (TransLab, #30-
04CLI19SSH). Samples were separated in a 10% SDS-
polyacrylamide gel electrophoresis and transferred
onto nitrocellulose membrane (GE Healthcare Life
Sciences, #10600023). After the membranes were
blocked in 5% skim milk for 1 h at room temperature,
they were incubated with primary antibodies over-
night at 4 °C and then with the corresponding sec-
ondary antibodies for 1 h at room temperature. All of
the primary antibodies gp91-phox antibody (Santa
Cruz Biotechnology, #K0817) and β-actin (Cell Signal-
ing, #4970 s) were used at a dilution of 1:1000 except
DUOX1 (Santa Cruz Biotechnology, #B2817) (1:500)
and DUOX2 (Santa Cruz Biotechnology, #D0317) (1:
500). Secondary antibodies were used at 1:2500 dilu-
tion. Immunoreactive bands were detected using the
enhanced chemiluminescence (ECL) detection system
with a PhosphorImager (GE Healthcare). Protein ex-
pression levels were normalized to the levels of the β-
actin, which was used as a loading control.
Patients samples
Frozen cervical cancer tissue samples were obtained
from some of patients with cervical cancer and their
controls were obtained from the cohort of the De-
partment of Obstetrics and Gynecology, Chungnam
National University Hospital (Daejeon, South Korea)
and were analyzed by western blot. In this study, each
three normal cervical cancer tissues, early-stage cer-
vical squamous cell carcinoma, advanced-stage cer-
vical squamous cell carcinoma, and endocervical
adenocarcinoma tissues deposited with the Human
Resources Bank of Korea in Chungnam National
University Hospital were used for this study.
Authorization for the use of these tissues for research
purposes and ethical approval were obtained from the
Institutional Review Board of Chungnam National
University Hospital (IRB number: 2019-05-087). Writ-
ten informed consents, which were approved by
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Institutional Review Board of Chungnam National
University Hospital, were received from the entire pa-
tients who had provided the tissue.
Functional enrichment analysis
Gene Set Enrichment Analysis (GSEA) was used to as-
sess enrichment of mRNAs associated with Hallmark
and Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways sets [15]. GSEA was conducted using the 10%
of CESC samples with the most strongly upregulated
DUOX1 and NOX2 expression and the 10% of samples
with the most strongly downregulated DUOX1 and
NOX2 expression. Enrichment maps were visualized in
Cytoscape v.3.5.1 (www.cytoscape.org). A p-value of less
than 0.05 was considered significant.
Analysis of immune cell subsets from mRNA expression
profiles
To quantify the relative abundances of 22 tumor-
associated leukocyte subsets in samples from HPV-
positive and -negative CESC patients, we utilized the
Cell type Identification By Estimating Relative Subsets
Of known RNA Transcript (CIBERSORT) method and
the LM22 gene signature, which allow for highly sensi-
tive and specific discrimination of hematopoietic cells
and were well-designed and validated based on gene ex-
pression profiles from Affymetrix Human Genome
U133A/Plus2 [16]. CIBERSORT analysis was conducted
using the 10% samples with the most strongly upregu-
lated DUOX1 and NOX2 expression and the 10% of
samples with the most strongly downregulated DUOX1
and NOX2 expression.
Survival analysis
Survival analysis of cervical cancer patients was per-
formed using GEPIA. The cumulative event (death) rate
was calculated by the Kaplan–Meier method, using the
time from the date of operation to the date of death as
the outcome variable. Survival curves stratified by risk
factors were compared by log-rank test, with p-values
less than 0.05 considered to indicate statistical signifi-
cance. The median group cutoff was median.
Statistical analysis
Data were analyzed in Prism version 5.0 (GraphPad
Prism Software, La Jolla, CA, USA) and Statistical Pack-
age for Social Sciences for Windows version 13.0 (SPSS,
Chicago, IL, USA). Distributions between two groups
were compared by t-test (or by Kolmogorov-Smirnov
test when the expected frequency in any group was less
than 5) for continuous variables, and by Chi-square test
(or Fisher’s exact test when the expected frequency in
any group was less than 5) for categorical variables.
Three or more groups were compared by one-way
analysis of variance. A p-value of less than 0.05 was con-
sidered significant.
Results
DUOX1 and DUOX2 are predominantly expressed in
cervical cancer patients
Clinicopathological characteristics of the patients are
listed in Table 1. mRNA and protein expression of
DUOX and NOX genes was examined in patients with
cervical cancer (Fig. 1). DUOX1 and DUOX2 expression
was increased by 57.9- and 67.5-fold, respectively,
whereas NOX4 expression was decreased by 0.17-fold in





≤ 50 years 188 (61.2)
> 50 years 119 (38.8)
Histological type
Squamous cell carcinoma 254 (82.7)
Endocervical adenocarcinoma 47 (15.3)













Non-keratininzing type 120 (39.1)




Human papilloma virus status
Negative 23 (7.5)
Positive (High risk) 284 (92.5)
Hpv 16 172 (56.0)
Hpv 18 39 (12.7)
Hpv 45 24 (7.8)
Hpv etc 47 (15.3)
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patients compared to normal control subjects (Fig. 1a).
DUOX1, DUOX2, and NOX2 protein expression were
also identified in our clinical cervical cancer samples
(Additional file 1). DUOX1 and DUOX2 were also the
most abundant NOX transcripts in cervical cancer
patients, whereas NOX3 was the least abundant and was
undetectable in normal control subjects (Fig. 1b and
Table 2). DUOX and NOX mRNA expression was sig-
nificantly different according to the presence of HPV in-
fection and histologic type. In cervical cancer patients
Fig. 1 mRNA and protein expression of NOX genes in cervical cancer. a Fold change in mRNA expression in comparison to normal control levels.
Data are from The Cancer Genome Atlas. b Relative mRNA expression of NOX genes in cervical cancer patients. c mRNA expression in patients
with and without HPV infection. d mRNA expression among patients with HPV 16, HPV 18, and HPV 45. e mRNA expression according to
histologic type in squamous cell carcinoma and adenocarcinoma. Six adenosquamous carcinoma cases were excluded from histologic
comparison. *p < 0.05; **p < 0.01; ***p < 0.001 by one-way ANOVA to compare more than two groups, or by t-test to compare two groups
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Table 2 Expression of the NADPH oxidase family in patients with cervical cancer






Mitogenic Oxidase (Pyridine Nucleotide-Dependent Superoxide-Generating) Xq22.1 1.21
NOX2 NADPH
Oxidase 2
CYBB (Cytochrome B-245 Beta Chain), Superoxide-Generating NADPH Oxidase Heavy Chain Sub-





Mitogenic Oxidase 2, NADPH Oxidase Catalytic Subunit-Like 3 6q25.3 NA
NOX4 NADPH
Oxidase 4
Kidney Superoxide-Producing NADPH Oxidase, Kidney Oxidase-1 11q14.3 0.17
NOX5 NADPH
Oxidase 5
NADPH Oxidase, EF-Hand Calcium Binding Domain 5 15q23 1.21
DUOX1 Dual
Oxidase 1
NADPH Thyroid Oxidase 1, Nicotinamide Adenine Dinucleotide Phosphate Oxidase, Flavoprotein




NADPH Thyroid Oxidase 2, Nicotinamide Adenine Dinucleotide Phosphate Oxidase 15q21.1 67.5
Fig. 2 Survival analysis of cervical cancer patients based on GEPIA data. a Kaplan–Meier survival analysis conducted with high and low mRNA
expression of DUOX1, DUOX2, and NOX2 regarding their associations with overall survival (b) Kaplan–Meier survival analysis conducted with high
and low mRNA expression of DUOX1, DUOX2, and NOX2 regarding their associations with disease-free survival
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with HPV infection, DUOX1 and DUOX2 mRNA levels
were significantly increased as compared to patients
without HPV infection (Fig. 1c). DUOX1 and DUOX2
mRNA levels were significantly higher in patients with
HPV 16 than in patients with HPV 18 and HPV 45 (Fig.
1d). In addition, mRNA and protein levels of DUOX1
and DUOX2 were higher in patients with cervical squa-
mous cell carcinoma than in those with endocervical
adenocarcinoma (Fig. 1e and Additional file 1). However,
mRNA levels of NOX family members were not signifi-
cantly associated with clinical stage and pathologic stage
(Additional file 2). Moreover, mRNA expression of
DUOX1, DUOX2, and NOX2 was also significantly in-
creased according to the GEPIA database, as shown in
Additional file 3. The normal tissues distribution of hu-
man DUOX1, DUOX2, and NOX2 is illustrated in Add-
itional file 4.
Cervical cancer patients with high expression of DUOX1
and NOX2 have a favorable prognosis
Based on the log-rank test in GEPIA, abundant mRNA
expression of DUOX1 (hazard ratio 0.45, 95% confidence
interval, p = 0.00082) and NOX2 (hazard ratio 0.63, 95%
confidence interval, p = 0.049) was significantly associ-
ated with better prognosis of CESC patients in terms of
overall survival (Fig. 2a). High mRNA expression of
DUOX1 (hazard ratio 0.45, 95% confidence interval, p =
0.0069) was significantly associated with better prognosis
of CESC patients in disease-free survival (Fig. 2b). In
addition, NOX1, NOX4, and NOX5 mRNA levels were
not significantly associated with the prognosis of cervical
cancer patients.
Immune pathways strongly associated with DUOX1 and
NOX2 expression
Using GSEA and enrichment network visualization, en-
richment of mRNAs associated with Hallmark pathways
and KEGG pathways (Fig. 3) were investigated in the
10% CESC samples with the most upregulated DUOX1
and NOX2 expression and in the 10% of samples with
the most downregulated DUOX1 and NOX2 expression.
In Hallmarks pathways, high DUOX1 and NOX2 mRNA
expression was significantly associated with immune
pathways related to interferon (IFN)-alpha and IFN-
gamma (Fig. 3a and Table 3). The NES (Normalized En-
richment Score) values of IFN-alpha and -gamma re-
sponses associated with DUOX1 were 2,17 and 1.85. The
NES values of IFN-gamma, inflammatory response, and
IFN-alpha responses related with DUOX2 were 2,93,
2.77, and 2.69, respectively.
In KEGG pathways, genes associated with immune
pathways, including NK cells, T-cell receptor, B-cell re-
ceptor, cytosolic DNA sensing, Toll-like receptor, and
retinoic acid-inducible gene-I (RIG-I) receptor were
significantly enriched under high DUOX1 mRNA ex-
pression. However, repression of DUOX1 mRNA expres-
sion significantly enriched for genes related with cancer-
related pathways, including focal adhesion, extracellular
matrix receptor interaction, transforming growth factor-
beta signaling, and cell adhesion (Fig. 3b). Meanwhile,
NOX2 expression enriched for several immune pathways
associated with cytokine cytokine-receptor interactions,
Janus kinase/signal transducers and activators of tran-
scription (JAK/STAT) signaling, intestinal immunity,
Toll-like receptor signaling, RIG-I receptor signaling,
cytosolic DNA sensing, T cell receptor, B cell receptor,
and NK cell signaling. However, drug-, xenobiotic-, and
retinol-metabolic pathways were significantly enriched
in samples with downregulated NOX2 mRNA expression
(Fig. 3b).
Innate and adaptive immune cell subsets are increased in
patients with high DUOX1 and NOX2 expression
CIBERSORT was used to estimate the abundances of
immune cell subsets and evaluate the changes in im-
mune cell subsets within tumor micro-environment in
cervical cancer (Fig. 4 and Additional files 5 and 6). The
analysis was carried out using the 10% samples with the
highest and lowest DUOX1 and NOX2 expression, and
revealed a change in abundance in 22 immune cell types
(Fig. 4a). Furthermore, the IHC staining of DUOX1 and
NOX2 protein was examined in cervical cancer based on
data from the Human Protein Atlas (Fig. 4b). It is
discovered that the IHC staining of DUOX1 was in-
creased in secretary cells of uterine cervical glands in
cervical cancer tissues. The NOX2 was selectively
stained intraepithelial infiltrating cells in cervical can-
cer tissue (Fig. 4b).
Next, we specifically investigated the changes in abun-
dance of adaptive and innate immune cells. Increased
abundances of innate immune cells, including NK cells,
monocytes, dendritic cells, and mast cells, and decreased
abundances of adaptive immune cells, including B cells,
CD8 T cells, and CD4 T cells, were identified in the
patients with high DUOX1 expression compared to the
patients with low DUOX1 expression (Fig. 4c). Addition-
ally, in the validation data set, high mRNA levels of
DUOX1 were also associated with increased innate
immune cells, including NK cells and mast cells, and a
decreased fraction of B cells (Additional file 5). On the
other hand, increased percentages of CD8 T cells and
follicular helper T cells and decreased percentages of B
cells and CD4 T cells in adaptive immune cells were
identified in patients with NOX2 high expression (Fig.
4d and Additional file 6). In innate immune cells, the
M1/M2 macrophage ratio and neutrophils were
increased in patients with high NOX2 expression
(Additional file 6).
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Discussion
We tried to identify new therapeutic targets for the
reinforcement of immune responses against HPV infection.
This study was the first to examine the immunologic role
and clinical significance of NADPH oxidase family mem-
bers in cervical cancer patients. We initially evaluated
DUOX1 and DUOX2 mRNA levels in the normal ectocer-
vix, endocervix, and vagina (Additional file 4). Interestingly,
we found that DUOX1 and DUOX2mRNA levels were dra-
matically increased in cervical cancer patients infected with
HPV 16 (Fig. 1d). DUOX1 and DUOX2 protein expression
were also identified in cervical squamous cell carcinoma
(Additional file 1). In line with our findings, a previous
study reported that DUOX and DUOX-derived ROS were
upregulated in the respiratory mucosa upon influenza virus
infection [17]. Moreover, in our study, high expression
levels of DUOX1 mRNA were significantly associated with
favorable overall survival as well as disease-free survival in
cervical cancer patients. Indeed, several studies were re-
ported that the relationship between expression and prog-
nostic effect of DUOX1 depend on the cancer tissue type.
For example, DUOX enzymes were first identified in
thyroid tissues and were found to be involved in thyroid
hormone biosynthesis [18–20]. In thyroid cancer,
DUOX1 is upregulated upon radiation, and DUOX1-
dependent H2O2 production promotes persistent DNA
damage and genome instability, which might contribute
to cancer development [21, 22]. In contrast, in the re-
spiratory tract, DUOX1 is mostly expressed in the tra-
cheal and bronchial epithelium [9], and DUOX1 mRNA
Fig. 3 Gene set enrichment analysis and map visualization for DUOX1 and NOX2 in cervical cancer. a Representative GSEA data with p values for
DUOX1 and NOX2 was shown. b Enrichment maps of DUOX1 and NOX2 in KEGG pathways. Red nodes represent enrichment in the former,
whereas blue nodes represent enrichment in the latter. Color intensity is proportional to the degree of enrichment, and clusters represent
functionally related gene sets. Data are for the 10% of samples with the most strongly upregulated DUOX1 and NOX expression and the 10% of
samples with the most strongly downregulated DUOX1 and NOX expression. The NES (Normalized Enrichment Score) computes the density of
modified genes in the dataset with the random expectancies, normalized by the number of genes found in a given gene cluster, to take into
account the size of the cluster
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and protein are suppressed in lung cancer as a consequence
of hypermethylation in the promoter region, and this sup-
pression is associated with poor prognosis [23–25]. More-
over, DUOX1 expression is low in the gastrointestinal tract
and has been detected in the stomach lining [24, 26]. In
gastric cancer, mRNA expression of DUOX1 was downreg-
ulated, whereas, high levels of DUOX1 mRNA were corre-
lated with poor prognosis, paradoxically [27]. It is
conceivable that the expression and prognostic effect of
DUOX1 depend on the organ and cancer type.
The role of DUOX2 has been actively investigated in
various malignancies [6, 23]. DUOX2 is the main iso-
form within the gastrointestinal tract and is expressed
most prominently within the colon epithelium and rectal
glands [9, 28]. It has been reported that strong DUOX2
expression accelerates the development of colorectal and
pancreatic cancers in patients with inflammatory bowel
disease and chronic pancreatitis, respectively [6].
Overexpression of DUOX2/DUOX2A during ulcerative
colitis is also thought to be responsible for oxidative
DNA damage, which predisposes these patients to colon
cancer development [29]. However, in our study,
DUOX2 mRNA was detected in the vagina, and rarely
detected on the cervix (Additional file 4). DUOX2
mRNA was also dramatically increased in cervical cancer
patients; however, high DUOX2 mRNA level was not as-
sociated with significant favorable prognosis. Moreover,
NOX2 mRNA was rarely detected on the cervix and va-
gina (Additional file 4). However, NOX2 mRNA was sig-
nificantly increased in cervical cancer patients with
HPV, and high NOX2 mRNA level was significantly as-
sociated with favorable overall survival. NOX2 protein
expression were also identified in cervical squamous cell
carcinoma and adenocarcinoma (Additional file 1). In-
deed, it has been indicated that high levels of NOX2
mRNA are implicated in promoting oncogenic
Table 3 Hallmark pathways of DUOX1 and NOX2 in cervical cancer
Term Size ES NES NOM p-val
DUOX1 – Hallmark pathways up
HALLMARK_INTERFERON_ALPHA_RESPONSE 97 0.57 2.17 0.00
HALLMARK_INTERFERON_GAMMA_RESPONSE 199 0.44 1.85 0.00
HALLMARK_ESTROGEN_RESPONSE_EARLY 197 0.39 1.63 0.00
HALLMARK_ESTROGEN_RESPONSE_LATE 200 0.37 1.56 0.00
HALLMARK_INFLAMMATORY_RESPONSE 200 0.29 1.19 0.09
HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 0.27 1.12 0.17
DUOX1 – Hallmark pathways down
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 199 −0.59 −2.43 0.00
HALLMARK_ANGIOGENESIS 36 −0.51 −1.62 0.01
HALLMARK_HEDGEHOG_SIGNALING 36 −0.47 −1.49 0.04
HALLMARK_KRAS_SIGNALING_UP 200 −0.34 −1.41 0.01
HALLMARK_WNT_BETA_CATENIN_SIGNALING 42 −0.39 − 1.29 0.11
HALLMARK_APICAL_JUNCTION 200 −0.30 −1.27 0.03
NOX2– Hallmark pathways up
HALLMARK_INTERFERON_GAMMA_RESPONSE 199 0.80 2.93 0.00
HALLMARK_INFLAMMATORY_RESPONSE 200 0.77 2.77 0.00
HALLMARK_INTERFERON_ALPHA_RESPONSE 97 0.81 2.69 0.00
HALLMARK_IL6_JAK_STAT3_SIGNALING 87 0.76 2.47 0.00
HALLMARK_IL2_STAT5_SIGNALING 198 0.63 2.30 0.00
HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 0.63 2.29 0.00
NOX2– Hallmark pathways down
HALLMARK_GLYCOLYSIS 199 −0.36 −1.50 0.00
HALLMARK_NOTCH_SIGNALING 32 −0.34 −1.05 0.37
HALLMARK_HEDGEHOG_SIGNALING 36 −0.28 −0.89 0.65
HALLMARK_FATTY_ACID_METABOLISM 156 −0.22 −0.88 0.80
HALLMARK_PROTEIN_SECRETION 96 −0.22 −0.83 0.89
HALLMARK_G2M_CHECKPOINT 194 −0.12 −0.52 1.00
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characteristics in breast cancer, rectal cancer, and pros-
tate cancer [30–32].
We conducted GSEA to verify the effects of DUOX1
and NOX2 on survival in cervical cancer patients. Not-
ably, expression of both DUOX1 and NOX2 was signifi-
cantly associated with immune pathways related to IFN-
alpha and IFN-gamma. IFN is well known to be import-
ant for tumor suppression because it not only directly
kills tumor cells, but also activates immune cells in the
tumor microenvironment [33]. In addition, estrogen re-
sponse and NK cell signaling pathways were closely re-
lated to DUOX1 expression. Moreover, the pathways of
TNF alpha and cytokine–cytokine receptor interaction
were closely related to NOX2 expression (Table 3). The
effects of DUOX1 and NOX2 on survival in cervical can-
cer patients depend commonly on IFN-alpha and IFN-
gamma, and differential pathways of DUOX1 and NOX2
were identified.
We investigated IHC staining of DUOX1 and NOX2
in cervical cancer tissues based on data from the Human
Protein Atlas. Specifically, we discovered that DUOX1
and NOX2 staining in uterine cervical glands and intrae-
pithelial infiltrating cells in cervical cancer tissues. These
findings are supported by several recent reports on the
presence of DUOX1 in non-epithelial cell types such as
T-cells [34], macrophages [35], and innate lymphoid
Fig. 4 Immune cell signatures in cervical cancer patients with DUOX1 and NOX2 expression. Estimated mRNA percentages of 22 immune cell
subsets (LM22 signature), as calculated by CIBERSORT, in cervical cancer patients with DUOX1 and NOX2 gene expression. a Relative percentages
of LM 22 signature subsets in patients with DUOX1 and NOX2 gene expression. b Immunohistochemical staining of DUOX1 and NOX2 adapted
from Human Protein Atlas. c Relative percentages of immune cells in patients with high and low DUOX1 mRNA expression. d Relative
percentages of immune cells in patients with high and low NOX2 mRNA expression
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cells [36], and the presence of NOX2 in phagocytes [37].
To investigate the immune cell types regulated by
DUOX1 and NOX2 mRNA expression in cervical cancer
tissues more specifically, we utilized CIBERSORT ana-
lysis. Notably, high mRNA levels of DUOX1 were closely
related with increased innate immune cells, especially,
NK cells, monocytes, dendritic cells, and mast cells, and
also with a decreased fraction of adaptive immune cells,
including B cells, CD8+ T, and CD4+ T cells. This indi-
cates that DUOX1 expression is highly associated with
the innate immune cell response in cervical cancer. Re-
cent evidence indicates that DUOX1 is expressed in in-
nate lymphoid cells, where it has potential roles in
innate lymphoid cell polarization, indicating broad host
defense functions of DUOX1 [36]. Moreover, the pa-
tients with high mRNA expression levels of NOX2 were
closely related with increased fractions of M1/M2 mac-
rophages and neutrophils among innate immune cells.
In addition, the patients with high mRNA expression
levels of NOX2 mRNA levels were related with increased
percentages of CD8+ T cells and follicular helper T cells
among adaptive immune cells. These findings indicate
that NOX2 expression is not only associated with phago-
cytes, such as macrophages and neutrophils [37], but
also with adaptive immune cells, including CD8+ and
follicular helper T cells. Based on GSEA and CIBER-
SORT analysis, it is suggested that DUOX1 and NOX2
have differential effects on the immune cell-mediated re-
sponse in cervical cancer patients. In the tumor micro-
environment, different types of infiltrating immune cells,
including macrophages, dendritic cells, mast cells, NK
cells, B cells, and effector T cells have diverse effects on
cancer progression [38]. Especially, NK cells collaborate
with dendritic cells to induce an immune response
against viral infections and tumors [39]. Activated den-
dritic cells also play an important role in tumor therapy
by acting as natural adjuvants, and tumor-specific fol-
licular helper T cells act as potent antigen-presenting
cells [40, 41]. In addition, an increased population of
mast cells was related with favorable prognosis [42]. In
this study, the increased mRNA levels of DUOX1,
DUOX2, and NOX2 in cervical cancer were identified in
TCGA and GEO databases. Moreover, the protein ex-
pression and their localization of DUOX1 and NOX2
were also confirmed in our own patient samples and
Human Protein Atlas database, respectively. However,
analyses presented here are mainly suggested on the
basis of different databases and there was still a chal-
lenge to experimentally validate the proposed underlying
mechanism in a large cohort of cervical cancer patients.
Conclusions
Our results suggest that DUOX1 and NOX2 mediate the
IFN-based immune defense against HPV infection, and
thereby affect the outcomes of cervical cancer patients.
This study has extended our knowledge of the roles of
DUOX1 and NOX2 in cervical cancer and shed light on
its potential clinical use in cervical cancer patients. The
approach of inducing a DUOX1 and NOX2-mediated
immune response in uterine cervical mucosa is clinically
expected to reinforce immune response to HPV infec-
tion and thus increase the survival of cervical cancer
patients.
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